SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
February 26 2021 - 7:30AM
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage
pharmaceutical company focused on the health security market, today
announced that management will host a webcast and conference call
to provide a business update at 4:30 P.M. ET on Thursday, March 4,
2021. Participating on the call will be Dr. Phil Gomez, Chief
Executive Officer, Daniel Luckshire, Chief Financial Officer, and
Dr. Dennis Hruby, Chief Scientific Officer.
A live webcast of the call will be available on
the Company's website at www.siga.com under the 'Events &
Presentations' tab in the Investor Relations section, or by
clicking here. Participants may also access the call by dialing
877-407-6184 for domestic callers or 201-389-0877 for international
callers. Please log in approximately 5-10 minutes prior to the
scheduled start time.
A replay of the call will be available for two
weeks by dialing 877-660-6853 for domestic callers or 201-612-7415
for international callers and using Conference ID: 13715918. The
archived webcast will be available in the Events and Presentations
section of the company's website.
ABOUT SIGA TECHNOLOGIES, INC. and
TPOXX®
SIGA Technologies, Inc. is a commercial-stage
pharmaceutical company focused on the health security market.
Health security comprises countermeasures for biological, chemical,
radiological and nuclear attacks (biodefense market), vaccines and
therapies for emerging infectious diseases, and health
preparedness. Our lead product is TPOXX®, also known as tecovirimat
and ST-246®, an orally administered and IV formulation antiviral
drug for the treatment of human smallpox disease caused by variola
virus. TPOXX is a novel small-molecule drug and the US maintains a
stockpile of 1.7 million oral courses in the Strategic National
Stockpile under Project BioShield. The oral formulation of TPOXX
was approved by the FDA for the treatment of smallpox on July 13,
2018. In September 2018, SIGA signed a contract with Biomedical
Advanced Research and Development Authority (BARDA) for additional
procurement and development related to both oral and intravenous
formulations of TPOXX. For more information about SIGA, please
visit www.siga.com.
About
Smallpox1
Smallpox is a contagious, disfiguring and often
deadly disease that has affected humans for thousands of years.
Naturally occurring smallpox was eradicated worldwide by 1980, the
result of an unprecedented global immunization campaign. Samples of
smallpox virus have been kept for research purposes. This has led
to concerns that smallpox could someday be used as a biological
warfare agent. A vaccine can prevent smallpox, but the risk of the
current vaccine's side effects is too high to justify routine
vaccination for people at low risk of exposure to the smallpox
virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are subject to various known and unknown
risks and uncertainties, and SIGA cautions you that any
forward-looking information provided by or on behalf
of SIGA is not a guarantee of future performance. More
detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth
in SIGA's filings with the Securities and Exchange
Commission, including SIGA's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, and in other
documents that SIGA has filed with
the SEC. SIGA urges investors and security holders
to read those documents free of charge at the SEC's web
site at http://www.sec.gov. Interested
parties may also obtain those documents free of charge
from SIGA. Forward-looking statements are current only as of
the date on which such statements were made, and except for our
ongoing obligations under the United States of
America federal securities laws, we undertake no obligation to
update publicly any forward-looking statements whether as a result
of new information, future events, or otherwise.
The information contained in this press release
does not necessarily reflect the position or the policy of the
Government and no official endorsement should be inferred.
_______________1
http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
Contact:
Daniel J. Luckshire
212-672-9100
investorrelations@siga.com
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Aug 2024 to Sep 2024
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Sep 2023 to Sep 2024